Abzena enhances AbZelectPRO™ cell line offering with new GS Knockout Platforms
The addition of the new GS knockout cell lines will further enhance speed, scalability, and flexibility for biopharma customers
26 Sept 2025
Abzena has announced the expansion of its AbZelectPRO™ cell line development (CLD) platform with the launch of two next-generation Glutamine Synthetase (GS) knockout CHO-K1 expression systems, including a double knockout ADCC+ platform for afucosylated proteins.
Named AbZelectPRO™-KO and AbZelectPRO™-KO+, the new GS knockout platforms are available as a standalone cell line development (CLD) offering or as a fully integrated GMP program, with fully transparent pricing to IND with no royalty fees. This flexible offering will enable customers to select a CLD strategy that aligns with their project-specific goals, timeline, and budget.
Licensed from Revvity, both GS knockout CHOSOURCE™ expression systems have been integrated into the AbZelectPRO™ CLD workflow and paired with ProteoNic Bioscience’s 2G UNic® next-generation vector technology. This unified approach has been proven to significantly enhance productivity and flexibility, enabling biopharma customers to quickly transition from DNA to research cell banks (RCB) in 10 weeks, with high-performing titers of up to 10 g/L.
Campbell Bunce, CSO of Abzena, said, “At Abzena, we consistently strive to build stronger partnerships with our customers by offering them innovative solutions and technologies that meet their needs across the drug development supply chain. The addition of these new GS knockout cell lines to our AbZelectPRO™ CLD platform is a powerful combination that truly sets a new standard of excellence. We are thrilled to offer such a robust, scalable, and state-of-the-art offering to support our customers’ therapeutic antibodies and difficult-to-express proteins.”
The CHOSOURCE™ Platform is available for research, clinical, diagnostic, and commercialization applications, including services, under specific licenses from Revvity.